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Abstract
Background: Atrial fibrillation is an important risk factor for ischemic stroke, and is associated with an increased risk of
poor outcome after ischemic stroke. Endovascular thrombectomy is safe and effective in acute ischemic stroke patients
with large vessel occlusion of the anterior circulation. This meta-analysis aims to investigate whether there is an
interaction between atrial fibrillation and treatment effect of endovascular thrombectomy, and secondarily whether
atrial fibrillation is associated with worse outcome in patients with ischemic stroke due to large vessel occlusion.
Methods: Individual patient data were from six of the recent randomised clinical trials (MR CLEAN, EXTEND-IA,
REVASCAT, SWIFT PRIME, ESCAPE, PISTE) in which endovascular thrombectomy plus standard care was compared to
standard care alone. Primary outcome measure was the shift on the modified Rankin scale (mRS) at 90 days. Secondary
outcomes were functional independence (mRS 0–2) at 90 days, National Institutes of Health Stroke Scale score at 24 h,
symptomatic intracranial hemorrhage and mortality at 90 days. The primary effect parameter was the adjusted common
odds ratio, estimated with ordinal logistic regression (shift analysis); treatment effect modification of atrial fibrillation
was assessed with a multiplicative interaction term.
Results: Among 1351 patients, 447 patients had atrial fibrillation, 224 of whom were treated with endovascular
thrombectomy. We found no interaction of atrial fibrillation with treatment effect of endovascular thrombectomy for
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both primary (p-value for interaction: 0.58) and secondary outcomes. Regardless of treatment allocation, we found no
difference in primary outcome (mRS at 90 days: aOR 1.11 (95% CI 0.89–1.38) and secondary outcomes between patients
with and without atrial fibrillation.
Conclusion: We found no interaction of atrial fibrillation on treatment effect of endovascular thrombectomy, and no
difference in outcome between large vessel occlusion stroke patients with and without atrial fibrillation.
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Introduction
Patients with acute ischemic stroke and atrial fibrilla-
tion (AF) present with a higher score on the National
Institute of Health Stroke Scale (NIHSS) more fre-
quently have intracranial arterial occlusion(s) and
have a worse functional outcome than patients without
AF.1,2 Furthermore, in patients with AF, treatment
with intravenous thrombolysis (IVT) is less effective
on both recanalisation and clinical outcome.3,4
Possible explanations are that emboli in AF are
larger and show a different pattern of occlusion than
emboli due to other causes. Endovascular thrombec-
tomy (EVT) is effective and safe in acute ischemic
stroke due to proximal intracranial large vessel occlu-
sion (LVO) of the anterior circulation.5–7 A post hoc
subgroup analysis of the MR CLEAN trial was com-
patible with decreased treatment effect in patients with
AF.8 However, as only a small number of patients was
included in this analysis, the uncertainty of this finding
was high. Our aim was to investigate whether AF
modifies treatment effect of EVT for acute ischemic
stroke due to LVO. Secondarily, we sought to deter-
mine whether AF was associated with worse outcome
in patients with ischemic stroke due to LVO.
Methods
Data collection
Data are from the “highly effective reperfusion using
multiple endovascular devices” (HERMES) collabora-
tion. The HERMES collaboration combined patient
level data available from clinical trials that used
second-generation mechanical devices (primarily stent
retrievers) to test if additional mechanical thrombec-
tomy (intervention group) is better than standard
care (control group) in patients with acute ischemic
stroke. For this purpose, individual patient data from
the MR CLEAN, ESCAPE, EXTEND-IA, SWIFT
PRIME, REVASCAT, PISTE, and THRACE trials
were pooled.5 The HERMES executive committee
(comprising representatives of each trial) confirmed
that all eligible trials were included and contributed
their trial data and the data were collated by an inde-
pendent biostatistician (SB). All participants or their
legal representatives provided informed consent
according to each trial protocol and each study was
approved by the local ethics board. The meta-analysis
was prospectively designed by the HERMES executive
committee, but not registered. AF status was known in
all of the aforementioned trials but the THRACE trial
whose data were therefore excluded.
Outcome measures
The primary outcome was the shift on the modified
Rankin Scale (mRS) score at 90 days. The mRS is a
score indicating the level of disability ranked between
0–6, with a score of 0–2 associated with functional
independence, an increased level of disability with a
score of 3–5, and a score of 6 indicating death.
Secondary outcome measures were functional indepen-
dence, defined as mRS 0–2 at 90 days, and stroke sever-
ity, measured with the NIHSS score, at 24 h after
stroke onset. Safety outcomes were symptomatic intra-
cranial hemorrhage (sICH) and mortality at 90 days.
The endpoints in the individual studies were measured
in person or by (telephone) interview; raters were
blinded to the study arm.
Clinical definitions
The diagnosis of AF was made when patient history
was positive for AF, or when AF was diagnosed during
hospital stay.
Statistical analysis
We performed an individual patient-level meta-analysis
based on the intention-to-treat principle. The primary
2 European Stroke Journal 0(0)
effect parameter was the adjusted common odds ratio
(acOR), estimated with ordinal logistic regression (shift
analysis). We assessed treatment effect modification by
AF with a multiplicative interaction variable on both
the primary and secondary outcomes. We adjusted the
primary and secondary effect parameters for potential
imbalances in major pre-specified confounding varia-
bles (age, stroke severity (NIHSS) at baseline, treat-
ment with IVT, localisation of occlusion and time
from onset to randomisation). We reported adjusted
and unadjusted common odds ratios with 95% confi-
dence interval (CI). We analysed binary outcomes with
logistic and linear regression respectively, and reported
as adjusted and unadjusted odds ratios or betas with
95% CIs, where applicable. All reported p-values are
two-sided. We performed all statistical analyses SAS
software, version 9.3, and R, version 3.2.
Results
In the six trials (MR CLEAN, EXTEND-IA,
REVASCAT, SWIFT PRIME, ESCAPE, PISTE),
1351 patients were included. Data on 90-day follow-
up were missing in 10 patients (Figure S1). AF was
present in 447 patients (33.1%) of whom 224 (50%)
were treated with EVT. At baseline, patients with AF
were older, less often treated with IVT, had a higher
ASPECTS score and more frequently suffered from
hypertension (Table 1, Table S1).
There was no significant difference in the treatment
effect size of EVT (acOR 2.39 (95% CI 1.47, 3.88) in
AF patients, acOR 2.34 (95% CI 1.66, 3.31) in patients
without AF) and no interaction of AF with treatment
effect of EVT (p-value for interaction 0.58) (Table 2,
Table S2). We also found no difference in functional
outcome between patients with and without AF (aOR
1.11 (95% CI 0.89, 1.38) (Table 3). For the secondary
outcomes, there was a trend towards a lower rate of
symptomatic intracranial hemorrhage in patients with
AF (aOR 0.57 (95% CI 0.3, 1.07)) (Table 3).
Discussion
In this individual patient data meta-analysis, we found
no significant modification of the effect of EVT by AF
on functional outcome, and secondary outcomes (func-
tional independence at 90 days, NIHSS score at 24 h,
symptomatic intracranial hemorrhage and mortality at
90 days). Additionally, in these patients with LVO,
the risk of poor outcome was not increased in patients
with AF.
A subgroup analysis of the MR CLEAN trial
showed a trend towards a lower treatment effect of
EVT in patients with AF.8 However, the number of
patients with AF in this study was rather low, therefore
no definite conclusion could be drawn. A meta-analysis
of 11 randomised controlled trials (RCT) comparing
EVT versus standard care found that good functional
outcome (mRS 0–2 at 90 days) after EVT occurred
more often in patients with AF.9 These meta-
analyses, however, also included several older, neutral
trials and did not adjust for treatment with IVT and
other potential confounders.
Our finding that in stroke patients with LVO of the
anterior circulation there is no difference in functional
outcome between patients with and without AF, is in
contrast with results of earlier studies in patients with
ischemic stroke in general, which found that patients
with AF had a worse clinical outcome, even after
IVT.3,4 However, in these studies populations with
other stroke types such as atherothrombotic or lacunar
strokes were included. Patients with AF more frequent-
ly suffer from proximal arterial occlusions, which over-
all leads to a poorer outcome than other types of
ischemic stroke. A likely explanation for our finding
is that we only looked at the subset of patients with
LVO, and that the underlying mechanism has less influ-
ence on stroke severity and outcome than the LVO
itself. The finding that baseline NIHSS does not signif-
icantly differ between patients with AF and those with-
out supports this notion.
We found a trend towards a lower rate of intracra-
nial hemorrhage in patients with AF (4.5% in patients
without AF vs 3.4% in patients with AF). However,
this difference did not reach significance (aOR 0.57;
95% CI 0.3–1.07). A significantly lower percentage of
AF subjects received IVT compared to patients without
AF (76.3% vs 90.6%). At baseline, patients with AF
were treated with tPA significantly less frequent than
patients without AF. This is likely due to the fact that
patients with AF are more likely to use oral anticoagu-
lation, which is a contra-indication for the administra-
tion of tPA.
Our results could imply that the lower percentage of
sICH in the AF group might be related to the lower
percentage of pre-treatment with IVT. The percentage
of sICH after treatment with IVT is around 5%.10
Considering this finding, the question arises whether
in patients with a proximal arterial occlusion treatment
with IVT prior to EVT is beneficial. Recent observa-
tional studies report conflicting results, some reporting
that pre-treatment with IVT before EVT is beneficial
for outcome,7,11,12 while others note there is no clear
benefit of pre-treatment while the risk of intracranial
hemorrhage is higher.13,14 Another issue is the delay
pre-treatment with IVT causes in patients also treated
with EVT. The main limitation of these studies is the
observational and retrospective design. Therefore,
more research into the benefit of IVT in patients with
proven LVO eligible for EVT is needed. Currently,
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there are several ongoing trials investigating this issue
(MR CLEAN NO-IV, DIRECT-MT, SWIFT
DIRECT, and DIRECT SAFE).
Strengths of this meta-analysis are the large number
of included of patients and the high prevalence of AF
(1351, 33% AF), leading to more reliable estimations.
Also, the uniform documentation of baseline character-
istics and outcome measures is a strength.
A limitation of this meta-analysis is that the pres-
ence of AF was documented in a binary way, meaning
it is not certain whether the patients were known with
AF before EVT, and whether it was paroxysmal or
chronic. Also, the duration of cardiac monitoring was
not recorded; therefore it cannot be excluded that the
monitoring varied between studies and individual
patients resulting in a diagnosis bias. Another limita-
tion is that data on anticoagulation status were not
available for all subjects, as there was no standardised
collection of such data across the studies that were
included in this meta-analysis. However, the fact that
fewer patients with AF were concurrently treated with
intravenous thrombolysis may suggest that many AF
patients were anticoagulated and therefore ineligible
for intravenous thrombolysis treatment. Furthermore,
no information on recurrent strokes following the ini-
tial event was recorded. This would have been interest-
ing data, considering the fact that in the initial period
following an ischemic stroke patients might temporar-
ily not be treated with anticoagulation, possibly leading
to a higher recurrence of ischemic stroke in this patient
group. However, as we found no difference in outcome
between patients with and without AF in this study, we
can deduce that a possibly higher rate of recurrence in
AF patients did not lead to an overall worse function-
ing at threemonths, when compared to patients with-
out AF. Lastly, the included data were derived from
randomised controlled trials randomising for EVT plus
standard treatment or standard treatment alone; there
was no stratification by AF status and therefore,
unmeasured confounders cannot be ruled out.
Conclusion
We found no interaction of AF with effect of EVT in
patients with AIS due to LVO. Furthermore, we found
no difference in the functional outcome between
patients with and without AF regardless of treatment,
suggesting that the cause of proximal arterial occlusion
does not influence outcome in AIS due to LVO.
Altogether, our data implies AF status should not
influence the decision to proceed to EVT.T
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